| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
119,920,000 |
| Market
Cap: |
2.48(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$14.96 - $32.96 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Denali Therapeutics is a biopharmaceutical company that discovers and develops therapeutics to defeat neurodegenerative diseases. Co.'s clinical-stage programs are: leucine-rich repeat kinase 2 inhibitor program to address Parkinson's disease; enzyme transport vehicle :IDS program, its lead brain-penetrant enzyme replacement therapy, enabled by its enzyme transport vehicle, which is designed to restore iduronate 2-sulfatase, and reduce glycosaminoglycans, both peripherally and in the brain, in patients with mucopolysaccharidosis II; and eukaryotic initiation factor 2 B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
97,506 |
194,997 |
252,199 |
526,275 |
| Total Sell Value |
$1,994,341 |
$3,816,456 |
$5,294,638 |
$13,483,252 |
| Total People Sold |
2 |
5 |
5 |
6 |
| Total Sell Transactions |
4 |
19 |
38 |
76 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ho Carole |
Chief Medical Officer |
• – – |
2018-11-15 |
4/A |
OE |
$5.28 |
$64,601 |
I/I |
12,235 |
195,625 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2018-11-15 |
4 |
AS |
$18.07 |
$316,157 |
I/I |
(17,500) |
165,890 |
|
- |
|
| Watts Ryan J. |
President and CEO |
• • – |
2018-11-15 |
4 |
AS |
$18.12 |
$246,236 |
I/I |
(13,588) |
2,729,304 |
|
- |
|
| Watts Ryan J. |
President and CEO |
• • – |
2018-11-13 |
4 |
AS |
$18.00 |
$85,428 |
I/I |
(4,746) |
2,742,892 |
|
- |
|
| Schuth Alexander O. |
COO and Secretary |
• – – |
2018-10-02 |
4 |
OE |
$5.28 |
$62,498 |
D/D |
7,043 |
12,961 |
|
- |
|
| Watts Ryan J. |
President and CEO |
• • – |
2018-10-01 |
4 |
AS |
$21.72 |
$398,193 |
I/I |
(18,333) |
2,747,638 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2018-10-01 |
4 |
AS |
$21.72 |
$380,100 |
I/I |
(17,500) |
183,390 |
|
- |
|
| Watts Ryan J. |
President and CEO |
• • – |
2018-09-04 |
4 |
AS |
$19.06 |
$349,427 |
I/I |
(18,333) |
2,765,971 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2018-09-04 |
4 |
AS |
$19.05 |
$333,375 |
I/I |
(17,500) |
200,890 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2018-08-29 |
4 |
AS |
$18.04 |
$315,700 |
I/I |
(17,500) |
218,390 |
|
- |
|
| Watts Ryan J. |
President and CEO |
• • – |
2018-08-29 |
4 |
AS |
$18.05 |
$330,929 |
I/I |
(18,334) |
2,784,304 |
|
- |
|
| Schuth Alexander O. |
COO and Secretary |
• – – |
2018-06-22 |
4 |
OE |
$5.28 |
$31,247 |
D/D |
5,918 |
5,918 |
|
- |
|
| Fil Ltd |
See Remark 1 |
– – – |
2017-12-12 |
4 |
A |
$0.00 |
$0 |
I/I |
1,775,856 |
1,379 |
|
- |
|
| Fil Ltd |
See Remark 1 |
– – – |
2017-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
1,497,951 |
1,914,833 |
|
- |
|
| Crestline Management, Lp |
10% Owner |
– – • |
2017-12-12 |
4 |
B |
$18.00 |
$4,950,000 |
I/I |
275,000 |
19,462,499 |
1.5 |
- |
|
| Crestline Management, Lp |
10% Owner |
– – • |
2017-12-12 |
4 |
A |
$0.00 |
$0 |
I/I |
19,986,798 |
1,111,799 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – – |
2017-12-12 |
4 |
A |
$0.00 |
$0 |
I/I |
3,238,676 |
33,215 |
|
- |
|
| Nelsen Robert |
Director |
– • • |
2017-12-12 |
4 |
A |
$0.00 |
$0 |
I/I |
10,756,249 |
11,068,749 |
|
- |
|
| Schenkein David P |
Director |
– • – |
2017-12-12 |
4 |
A |
$0.00 |
$0 |
I/I |
249,998 |
19,774 |
|
- |
|
| Flatley Jay T |
Director |
– • – |
2017-12-12 |
4 |
A |
$0.00 |
$0 |
I/I |
250,000 |
250,000 |
|
- |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2017-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
3,139,043 |
|
- |
|
| Flagship Ventures Fund V General Partner Llc |
10% Owner |
– – • |
2017-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
8,606,249 |
8,918,749 |
|
- |
|
| Watts Ryan J. |
President and CEO |
• • – |
2017-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
12,500 |
|
- |
|
| Bybee Clinton |
10% Owner |
– – • |
2017-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
10,756,249 |
11,068,749 |
|
- |
|
| Sato Vicki L |
Director |
– • – |
2017-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
137,500 |
|
- |
|
426 Records found
|
|
Page 17 of 18 |
|
|
0.29 (1.42%) 
